Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 5 de 5
Filtrer
1.
Eur Rev Med Pharmacol Sci ; 21(7): 1568-1575, 2017 04.
Article de Anglais | MEDLINE | ID: mdl-28429349

RÉSUMÉ

OBJECTIVE: Obstructive Sleep Apnea (OSA) has been associated with both subclinical and accelerated atherosclerosis; however, it still remains unknown whether this association is unique or is mediated by the higher burden of co-existing cardio-metabolic disorders frequently seen in patients with OSA. PATIENTS AND METHODS: A total of 40 subjects without clinically diagnosed cardiovascular disease (CVD) referred for polysomnography test were included in the study. Subjects with apnea/hypopnea index (AHI > 15/h) were classified as moderate/severe OSA. Subclinical changes in carotid atherosclerosis were assessed using mean carotid intima-media thickness (cIMT) and presence of atheromatic plaques on both carotid arteries. The measurement was performed using B-mode ultrasonogram. Framingham risk score was used in the approximation of cardiovascular risk. RESULTS: The mean age of our cohort was 56.8 years, 70% (n = 28) of whom were males. Moderate/severe OSA was diagnosed in 21 subjects. Both groups were well matched in terms of clinical and demographic characteristics, and cardiovascular risk profile, as shown in their respective Framingham risk scores (10.4 ± 6.6 vs. 11.8 ± 8.8, p = NS). Patients with moderate/severe OSA had a higher mean AHI, 3% oxygen desaturation index, and lower minimum nocturnal oxygen saturation than controls. No significant differences were detected in terms of C-reactive protein levels. The two groups had similar cIMT (0.66 ± 0.17 vs. 0.75 ± 0.20 p = 0.33) and presence of atheromatic plaque (50% vs. 45%, p = 1.00). CONCLUSIONS: Our study suggests that among patients with similar cardiovascular risk profile and free of overt CVD, the severity of newly diagnosed OSA was not correlated with increased inflammation or subclinical carotid atherosclerosis.


Sujet(s)
Maladies cardiovasculaires , Artériopathies carotidiennes , Syndrome d'apnées obstructives du sommeil , Épaisseur intima-média carotidienne , Femelle , Humains , Mâle , Adulte d'âge moyen , Polysomnographie , Facteurs de risque , Syndrome d'apnées obstructives du sommeil/diagnostic
2.
J Chemother ; 19(4): 438-43, 2007 Aug.
Article de Anglais | MEDLINE | ID: mdl-17855189

RÉSUMÉ

With 69 years being the median age at diagnosis in the United States, management of elderly patients with advanced non-small cell lung cancer (NSCLC) has become a common problem faced by the oncology practitioner. We evaluated a biweekly administration of the combination regimen using docetaxel (Sanofi Aventis, Athens) and gemcitabine (Eli Lilly, Athens) in a phase II study (objective response rate, median survival, median response duration and safety). A total of 198 cycles were administered to 38 patients with advanced NSCLC with a median age of 72 years (range 65-85 years). Patients received docetaxel 80 mg/m(2 )and gemcitabine 1000 mg/m (2 )on days 1 and 14 of a 28-day cycle. Twenty patients achieved a partial response (PR) (20/34, 58.8%), 4 patients had stable disease (SD) (4/34, 11.7%) and 10 (10/34, 29.4%) had progressive disease (PD). The median time to disease progression was 3 months (range 1-11 months) with a mean survival of 7 months (range 1-29 months). Hematological and non-hematological toxic effects were generally mild to moderate and manageable: grade 3 neurotoxicity and grade 3 allergy occurred in 5 patients (13.1%) and 1 patient (2.6%), respectively. Peripheral neuropathy, mostly grades 1 and 2, was reported in 29 patients (76.3%), which was seen more frequently in patients >70 years of age (P=0.048).We conclude that the biweekly administration of a docetaxel/gemcitabine combination with G-CSF support constitutes a tolerable and convenient regimen for the treatment of elderly patients with advanced NSCLC, with efficacy similar to that reported in other regimens. Hence, this two-drug combination appears promising and warrants further evaluation.


Sujet(s)
Protocoles de polychimiothérapie antinéoplasique/administration et posologie , Carcinome pulmonaire non à petites cellules/traitement médicamenteux , Désoxycytidine/analogues et dérivés , Tumeurs du poumon/traitement médicamenteux , Taxoïdes/administration et posologie , Sujet âgé , Sujet âgé de 80 ans ou plus , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Carcinome pulmonaire non à petites cellules/mortalité , Désoxycytidine/administration et posologie , Désoxycytidine/effets indésirables , Docetaxel , Calendrier d'administration des médicaments , Femelle , Humains , Tumeurs du poumon/mortalité , Mâle , Taxoïdes/effets indésirables , Résultat thérapeutique , Gemcitabine
3.
Skeletal Radiol ; 36(8): 791-6, 2007 Aug.
Article de Anglais | MEDLINE | ID: mdl-17483943

RÉSUMÉ

A rare but distinctive variant of smooth muscle tumours that occurs almost exclusively in the uterus is characterised by the presence of plexiform tumourlets, which are composed of clumps and cords of tumour cells that form a discrete pseudoepithelial component. We report on a case of a primary leiomyosarcoma of the proximal humerus, which, in addition to characteristic histological and immunophenotypic features of leiomyosarcoma, contained plexiform tumourlets. Tumour cells in the plexiform component focally expressed muscle/smooth muscle actin, calponin and cytokeratin. Spindle-shaped and epithelioid smooth muscle tumour cells also expressed the above antigens. This is the first report of a plexiform smooth muscle tumour arising in bone. This case is remarkable, not only for being only the second reported case of a malignant plexiform smooth muscle tumour, but also for being one of very few examples of this type of tumour arising outside the uterus; it also is unique in having arisen in a male patient. This variant of primary leiomyosarcoma needs to be distinguished from other bone tumours containing epithelial elements, notably metastatic carcinoma.


Sujet(s)
Tumeurs osseuses/diagnostic , Humérus/anatomopathologie , Léiomyosarcome/diagnostic , Tumeurs épithéliales épidermoïdes et glandulaires/diagnostic , Adulte , Marqueurs biologiques tumoraux , Biopsie , Tumeurs osseuses/complications , Tumeurs osseuses/chirurgie , Diagnostic différentiel , Études de suivi , Fractures spontanées/étiologie , Humains , Léiomyosarcome/complications , Léiomyosarcome/chirurgie , Imagerie par résonance magnétique , Mâle , Tumeurs épithéliales épidermoïdes et glandulaires/complications , Tumeurs épithéliales épidermoïdes et glandulaires/chirurgie , Prothèses et implants , Radiographie , Maladies rares , Épaule/imagerie diagnostique , Épaule/anatomopathologie , Épaule/chirurgie , Fractures de l'épaule/étiologie , Scapulalgie/étiologie , Résultat thérapeutique
4.
J Telemed Telecare ; 11 Suppl 1: 86-8, 2005.
Article de Anglais | MEDLINE | ID: mdl-16036007

RÉSUMÉ

Eighteen well motivated patients with advanced chronic obstructive pulmonary disease, who had had at least four hospitalizations during the previous two years, were included in a home-based telemedicine study. A visiting nurse was equipped with a case containing a laptop computer and a number of medical devices, including an electrocardiogram recorder, spirometer, oximeter and blood pressure monitor. It also contained a videoconference camera, for realtime audiovisual connection with the hospital using the patient's TV set. A single ISDN line (128 kbit/s) was installed in each house before the study began. After nine months, there was a decrease in hospitalizations, emergency department visits and use of health services. The patient's disease knowledge and self-management also improved. It seems likely that adopting telemedicine in everyday clinical practice could substantially improve the care of chronically ill patients.


Sujet(s)
Services de soins à domicile , Broncho-pneumopathie chronique obstructive/thérapie , Télémédecine/méthodes , Urgences , Hospitalisation/statistiques et données numériques , Humains , Systèmes informatisés de dossiers médicaux , Acceptation des soins par les patients , Éducation du patient comme sujet/méthodes , Autosoins/méthodes , Télémédecine/instrumentation
5.
Histol Histopathol ; 17(1): 131-8, 2002 01.
Article de Anglais | MEDLINE | ID: mdl-11813863

RÉSUMÉ

Activation of telomerase, present in the vast majority of all human cancers, is associated with elongation of chromosomal telomeres and consequent cell immortalization. Telomere length homeostasis is a dynamic process governed by the negative feedback mechanism of the telomeric repeat binding factor 1 (TRF1) which inhibits the action of telomerase in telomerase-positive cells. In an attempt to investigate markers of tumour growth as possible prognostic indicators in laryngeal cancer, we studied the expression of TRF1 and of the proliferation marker Ki67 on 96 invasive squamous carcinomas of the larynx. A standard three step immunoperoxidase staining method was applied on paraffin sections incubated with appropriate polyclonal antibodies. The percentages of Ki67- and TRF1-immunopositive cancerous cells were calculated by image analysis. Univariate and multivariate statistical analysis of the staining results were performed in order to detect any association of the examined immunomarkers with the tumours' classical clinicopathological variables including nuclear morphometric features as well as with patients' disease-free survival. Ki67 immunostaining was positively linked with advanced patients' age, nodal involvement as well as presence of early recurrence. No relation was found between proliferative fraction and TRF1 immunoexpression. TRF1 was expressed in 55.2% of all cases and was positively linked only to tumour size. Multivariate statistical analysis revealed the presence of lymph nodal metastasis and Ki67 immunopositivity index > or = 20% as significant predictors of relapse. Increased Ki67 immunostaining appears to be a promising marker of tumour aggressiveness in laryngeal cancer. After one point at the tumour's natural history, the maintenance of tumour growth does not seem to depend on cell proliferation but on TRF1 immunoexpression. Whether the latter can be used for the identification of immortalized cells in every-day practice is worth investigating.


Sujet(s)
Carcinome épidermoïde/métabolisme , Carcinome épidermoïde/anatomopathologie , Protéines de liaison à l'ADN/métabolisme , Tumeurs du larynx/métabolisme , Tumeurs du larynx/anatomopathologie , Adolescent , Adulte , Sujet âgé , Enfant , Femelle , Humains , Immunohistochimie , Antigène KI-67/biosynthèse , Modèles logistiques , Mâle , Adulte d'âge moyen , Récidive tumorale locale , Inclusion en paraffine , Valeur prédictive des tests , Pronostic , Survie , Télomère/métabolisme , Protéine-1 se liant aux répétitions télomériques , Fixation tissulaire
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE